Clinical Trials Logo

Clinical Trial Summary

Eligible research subjects will receive an unrelated umbilical cord blood transfusion as a possible cure for their inherited metabolic disease. A portion of cord blood cells (ALD-101) will be separated from the cord blood unit and given approximately 4 hours after the standard cord blood transfusion.

The study will test if the supplemental cells will increase the speed at which normal levels of circulating blood cells are re-established after transplant.


Clinical Trial Description

Subjects will be hospitalized and undergo high doses of chemotherapy which will destroy the child's normal cells including their bone marrow (which forms blood cells) in order to prepare their body for the umbilical cord blood transplant. The cord blood transplant is intended to rescue your child's bone marrow from the bad effects of the procedure. The child will receive 80% of a standard cord blood transplant followed by 20% supplemental stem cell called ALD-101.

The study will evaluate if these cells (ALD-101) will repopulate the bone marrow more rapidly after transplant. This would shorten the period of time that the transplanted subject would be at risk for infection and bleeding and would also decrease the number of red blood cell and platelet transfusions needed.

ALD-101 has been used as a supplement to cord blood transplant in twenty-eight children with genetic diseases and malignancy in one previous clinical study that is on-going.

The main purpose of this research study is to test whether a portion of cord blood cells that have been separated from a cord blood unit (ALD-101) will increase the speed at which normal levels of circulating blood cells are re-established after transplant. This is the experimental part of this study. ALD-101 is also being tested to see if it is safe. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00654433
Study type Interventional
Source Aldagen
Contact
Status Terminated
Phase Phase 3
Start date March 2008
Completion date November 2011

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03548779 - North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2 N/A
Completed NCT01049854 - CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant Phase 2
Completed NCT00001596 - Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome Phase 2
Withdrawn NCT01003912 - Fetal Umbilical Cord Blood (UCB) Transplant for Lysosomal Storage Diseases Phase 1
Completed NCT00744692 - Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders Phase 1
Completed NCT00692926 - Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells Phase 1
Recruiting NCT05818566 - Orphan Drugs for Inherited Metabolic Diseases
Completed NCT05330039 - Characterization of Intestinal Microbiota in Children With Inborn Errors of Metabolism (IEM)
Withdrawn NCT03866954 - Trial of Erythrocyte Encapsulated Thymidine Phosphorylase In Mitochondrial Neurogastrointestinal Encephalomyopathy Phase 2
Completed NCT03911089 - A Collection of Case Studies in Infants With UCD to Evaluate Infant Growth and the Safety of a New Medical Food for UCD N/A
Completed NCT03058848 - Evaluation of PKU Start N/A
Suspended NCT04399694 - Identification and Characterization of Novel Non-Coding Variants That Contribute to Genetic Disorders
Completed NCT03168399 - Evaluation of PKU Explore N/A
Recruiting NCT00078078 - Clinical and Laboratory Study of Methylmalonic Acidemia
Completed NCT00328159 - Nutritional Therapy of the Deficits of Oxidation Mitochondrial of the Fatty Acids N/A
Completed NCT04309331 - Market Research - Acceptability Trial for a New PKU Amino Acid Based Protein Substitute N/A
Completed NCT04709965 - Evaluating Face-Recognition Technology in Syndrome Diagnosis N/A
Recruiting NCT06360913 - Blood Spot and Urine Metabolomic Screening Applied to Rare Diseases N/A
Completed NCT00309400 - The Early History of Universal Screening for Metabolic Disorders N/A
Completed NCT00004378 - Stem Cell Transplantation (SCT) for Genetic Diseases N/A